TY -的T1 -全球结核病预防:商店uld we start from the beginning? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01394-2019 VL - 54 IS - 3 SP - 1901394 AU - Sotgiu, Giovanni AU - Goletti, Delia AU - Matteelli, Alberto Y1 - 2019/09/01 UR - //www.qdcxjkg.com/content/54/3/1901394.abstract N2 - Tuberculosis (TB), which is estimated to be the deadliest infectious disease worldwide with ∼1.6 million deaths yearly [1], is a clinical issue due to the “ancient” diagnostics and drugs currently available. If compared with the management of other highly prevalent infectious diseases, such as HIV/AIDS and hepatitis C virus infection, it is clear that the clinical approach for TB disease requires innovation, being still based on means with limited efficacy (e.g. treatment of multidrug-resistant TB; MDR-TB), and characterised by the denominator “long duration”: conventional bacteriological diagnosis, therapy for the drug-susceptible disease (i.e. 6 months) and MDR-TB (i.e. >20 months) [2–7].TB prevention should be based on a global and local comprehensive assessment of LTBI burden http://bit.ly/2YfKM0T ER -